

Appendix A

<b>Measures Finalized in FY 2015 IPPS/LTCH</b>		
<b>Measure Domain</b>	<b>NQF Endorsement Number</b>	<b>Measure Name</b>
Patient Safety	0139	Central Line-Associated Bloodstream Infection (CLABSI)
	0138	Catheter-Associated Urinary Tract Infection (CAUTI)
	0753	Harmonized Procedure Specific Surgical Site Infection (SSI) Outcome Measure
Cancer Specific Treatment	0223	Adjuvant Chemotherapy is considered or administered within 4 months (120 days) of diagnosis to patients under the age of 80 with AJCC Stage III (lymph node positive) colon cancer
	0559	Combination Chemotherapy is considered or administered within 4 months (120 days) of diagnosis for women under 70 with AJCC T1c, or Stage II or III hormone receptor negative breast cancer
	0220	Adjuvant Hormonal Therapy
Improvement Project (SCIP)Surgical Care	0218	Surgery Patients who Received Appropriate VTE Prophylaxis within 24 Hrs Prior to Surgery to 24 Hrs After Surgery End Time
	0284	Surgery Patients on Beta Blocker Therapy Prior to Admission who received a Beta Blocker during the Perioperative Period
	0453	Urinary Catheter Removed on Post-Operative Day 1 or Post-Operative Day 2 with Day Surgery Being Day Zero
	0527	Prophylactic Antibiotic Received Within 1 Hr Prior to Surgical Incision
	0528	Prophylactic Antibiotic Selection for Surgical Patients

	0529	Prophylactic Antibiotic Discontinued Within 24 Hrs After Surgery End Time
Oncology Care Measures	0382	Oncology-Radiation Dose Limits to Normal Tissues
	0383	Oncology: Plan of Care for Pain
	0384	Oncology: Pain Intensity Quantified
	0390	Prostate Cancer-Adjuvant Hormonal Therapy for High-Risk Patients
	0389	Prostate Cancer-Avoidance of Overuse Measure-Bone Scan for Staging Low-Risk Patients
	0166	HCAHPS Patient Experience of Care Survey
Clinical Effectiveness	1822	External Beam Radiotherapy (EBRT)